Skip to main content

Table 2 Treatments received by LOT

From: Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Treatment, n (%) 1LOT 2LOT 3LOT
Received treatment 652 184 18
Sunitinib 396 (60.7%) 1 (0.5%)
Originally prescribed 375 (57.5%) 1 (0.5%)
Pazopanib intolerant 21 (3.2%)
Pazopanib 246 (37.7%)
Originally prescribed 209 (32.1%)
Sunitinib intolerant 37 (5.7%)
Axitinib 105 (57.1%) 4 (22.2%)
Everolimus 4 (0.6%) 77 (41.9%) 13 (72.2%)
Other 6 (0.9%) 1 (0.5%) 1 (5.6%)
On treatment at FU 140 (21.5%) 48 (26.1%) 6 (33.3%)
  1. LOT Line of therapy, FU Follow-Up